BP 1.3656B
Alternative Names: BP 1.3656; BP1.3656B; BP13656Latest Information Update: 10 Aug 2022
At a glance
- Originator Bioprojet
- Class
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholism; Fatigue
- No development reported CNS disorders
Most Recent Events
- 27 Jul 2022 Phase-II clinical trials in Fatigue in France (PO) (NCT05240560)
- 17 Feb 2022 Bioprojet plans a phase II trial for Fatigue (PO, tablet) in France and Switzerland in March 2022 (NCT05240560)
- 24 Nov 2021 Bioprojet completes a phase II trial in Alcoholism in Bulgaria, France, Netherlands and Russia (PO) (NCT03424824)